Save up -80% on Ruxolitinib

Note: this is a drug discount program, not an insurance plan.

RX BIN: 015558
Group ID: DDN6600
Card Holder ID: DDN6600

Pharmacists and Patients support.

2018 Price of Ruxolitinib


* price without discount in nearest pharmacy. Price may vary.

Claim your free Ruxolitinib discount card

We offer free Ruxolitinib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Ruxolitinib every time. What are you waiting for? Claim your prescription drug card now!

Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time

Ruxolitinib volume of distribution

Terminal phase volume of distribution, 15 mg, healthy subject = 76.6 L.

About RX24Drugs

Discount Cards 16,000+

Clients Benefit 29%

Total savings $4,735,080

What is Ruxolitinib

Ruxolitinib is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. FDA approved on November 16, 2011.

Ruxolitinib mechanism of action

Ruxolitinib is a kinase inhibitor that is selective for the Janus Associated Kinases (JAK) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (STAT) which modulate gene expression. Patients with myelofibrosis have abnormal JAK1 and JAK2 activity thus ruxolitinib works to regulate this.

Dosage forms of Ruxolitinib

Tabletoral10 mg/1
Tabletoral15 mg/1
Tabletoral20 mg/1
Prescription Generics


International Brands



INCB018424 INCB424


Incyte Corporation

CAS number






Affected organisms

Humans and other mammals

Indication of Ruxolitinib

Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis.[Lexicomp]Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).

Toxicity of Ruxolitinib

Thrombocytopenia was the dose-limiting toxicity.

RX24 Drugs Disclaimer: before buying a Ruxolitinib on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Ruxolitinib now!